GH Form 4: Director Tariq Musa reports sale, 7,458 shares held

Rhea-AI Filing Summary

Director Tariq Musa reported a sale of Guardant Health (GH) common stock. On 08/19/2025 Mr. Musa sold 116 shares at $59.02 per share, leaving him with 7,458 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 08/20/2025 and indicates the transaction was a sale by the reporting person.

Positive

• Timely disclosure of the insider transaction via a filed Form 4
• Specific transaction details provided: date, number of shares, price, and post-transaction ownership

Negative

• Director sale (116 shares) could be perceived negatively by some investors despite lack of context
• No stated reason for the sale is provided in the filing

Insights

Financial Analyst

TL;DR: Routine insider sale of 116 shares by a director; small absolute size and limited apparent market impact.

The reported sale on 08/19/2025 of 116 shares at $59.02 reduces the director's stake to 7,458 shares. The filing provides exact trade date, price and post-transaction beneficial ownership, enabling straightforward disclosure analysis. There is no information in the Form 4 about the reason for the sale or any changes to trading plans beyond the checked box indicating a Rule 10b5-1 plan may apply.

Corporate Governance Expert

TL;DR: Filing meets Section 16 reporting requirements; the disclosure supports transparency but gives no governance signal.

The Form 4 is properly executed and discloses a director-level disposition. It documents compliance with reporting rules and identifies an attorney-in-fact signature. The form does not state any change in board role, nor any material event affecting governance. Without additional context on timing or proportionate holdings, the transaction appears routine.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tariq Musa

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		S		116	D	$59.02	7,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Musa Tariq	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health director Tariq Musa report on Form 4 (GH)?

He reported a sale of 116 shares of Guardant Health common stock on 08/19/2025 at a price of $59.02 per share.

How many Guardant Health shares does Tariq Musa own after the transaction?

The Form 4 reports 7,458 shares beneficially owned following the reported sale.

Was the Form 4 for Tariq Musa signed and when?

Yes, the Form 4 bears an attorney-in-fact signature dated 08/20/2025.

Does the filing indicate the sale was part of a 10b5-1 plan?

The form includes a checked box indicating a transaction pursuant to a plan intended to satisfy the Rule 10b5-1 affirmative defense.

Does the Form 4 disclose any derivative transactions for Tariq Musa?

No; Table II for derivative securities contains no reported transactions or holdings.